Also Included In: Cancer / Oncology
Article Date: 11 Jul 2013 - 2:00 PDT Current ratings for:
ARC Linkage Grant To Support Patrys' Partnership With Macquarie University For Development Of Cancer Diagnostics
Patrys Limited (ASX: PAB), a clinical stage biotechnology company, announced today that scientific collaborators at Macquarie University (Macquarie), Sydney, have been awarded a $427,510 Australian Government grant to support the development of new highly sensitive, non-invasive cancer diagnostic kits using Patrys' lead candidate PAT-SM6.
PAT-SM6 is an IgM antibody that has successfully completed a Phase I trial in melanoma and is currently in a Phase I/IIa trial for patients with relapsed or refractory multiple myeloma.
The grant, which has been awarded by the Australian Research Council ("ARC"), will bring together experts from Macquarie led by Dr. Dayong Jin, Professor Nicolle Packer, Professor James Piper, Associate Professor Robert Willows and Professor Simon Foote with industry partners Minomic International Limited and Patrys.
The project will combine Macquarie's new Super Dot nanocrystal technology with Minomic's and Patrys' antibodies directed against prostate and multiple myeloma cancer biomarkers, respectively.
Patrys' previous collaboration with Professor Packer showed that PAT-SM6 detects specific changes in the proteins present on the surface of multiple myeloma cells, but not on normal cells. These cancer-modified cells in the patients' blood and urine are very rare in early stages of disease and their detection poses a "needle-in-a-haystack" challenge at both the research and clinical levels. Current diagnostic tests are not sensitive enough to detect these rare-event cells, resulting in an inefficient early detection and diagnosis of cancer and consequently poor prognosis.
Dr. Jin and colleagues from Macquarie University have developed highly sensitive technologies using super-bright nanocrystals that will enable the detection of single abnormal cells in body fluids, and will provide the basis for new, sensitive and non-invasive, early-stage screening of multiple myeloma, prostate cancer and other malignancies.
Patrys CEO, Dr. Marie Roskrow, said: "Patrys is very proud to be part of this exciting and cutting-edge project and welcomes the opportunity to explore the innovative aspects of Patrys' antibodies. The possibility to use Patrys' antibodies as cancer diagnostics as well as therapeutics is very exciting and potentially brings additional opportunities and value to the Patrys' pipeline."
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.Visit our pharma industry / biotech industry section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:
MLA
11 Jul. 2013.
Please note: If no author information is provided, the source is cited instead.
'ARC Linkage Grant To Support Patrys' Partnership With Macquarie University For Development Of Cancer Diagnostics'
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
No comments:
Post a Comment